Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

ABSTRACT: This study proposes to determine the safety of the administration of E7820 plus cetuximab and explore the MTD of the combination in a Phase Ib study. In addition, the efficacy of this combination will be explored in patients with colorectal cancer in the Phase II proof of concept phase of the study.

DISEASE(S): Colorectal Neoplasms,Advanced Colorectal Cancer

PROVIDER: 2027665 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

Project description:This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA content and integrity. Pre-treatment gene expressions impacted clinical response, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.

2015-11-11 | GSE66999 | GEO

Diagnosis of hepatocellular adenomas and malignancy determination by proteomic patterns matching (2)

Project description:Biopsies are underrated and underused and our goal was to demonstrate that their inherent expression proteomic pattern could give them an added value for diagnosis. As proof of concept, we used as model hepatocellular adenomas (HCA), well characterized benign liver tumors. From a collection of 260 cases, we selected 55 typical cases to build the first HCA proteomic database. Biopsies proteomic patterns allowed HCA classification, even for complex cases. In addition, these data gave access to a malignancy pattern identifying the HCA transformation. This pioneering work proposes a proteomic based machine learning tool, operational on fixed biopsies, to improve HCA diagnosis and therefore patientâ€™s management.

2021-06-11 | PXD022837 | Pride

Diagnosis of hepatocellular adenomas and malignancy determination by proteomic patterns matching (1)

2021-06-11 | PXD022835 | Pride

Diagnosis of hepatocellular adenomas and malignancy determination by proteomic patterns matching (3)

2021-06-11 | PXD022839 | Pride

Diagnosis of hepatocellular adenomas and malignancy determination by proteomic patterns matching (4)

2021-06-11 | PXD022844 | Pride

Diagnosis of hepatocellular adenomas and malignancy determination by proteomic patterns matching (5)

2021-06-11 | PXD023000 | Pride

Targeted tracing, detection and Fishing of P53 protein based on a novel DNA sequence derivative probe

Project description:In this study, we report a novel sDNA sequence can specifically target P53 protein. As a proof of concept, we derivatized this new sDNA fragment and attached biotin at its 5'end. using chemical proteome methods, we explored the new sDNA enrichment ability of P53 protein.

2020-07-02 | PXD020147 | iProX

Project description:Proof of concept of massively PCR barcoding

| PRJNA765590 | ENA

LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615)

Project description:Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of LY3200882/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the LY3200882 plus capecitabine combination in patients with chemo-resistant CRC. The combination of LY3200882 plus capecitabine will be given as second line therapy in the phase II part of this study. Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined with oxaliplatin and, depending upon local hospital preferences or national guidelines, also bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of LY3200882 to capecitabine should thus result in reversal of unresponsiveness, which is the first step in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced CRC and is thus attractive for this study concept. If proof of principle is achieved also other tumor types can be explored with this genetic makeup, such as non-small cell lung cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line, usually cisplatin/carboplatin-pemetrexed in non-squamous and cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.

| 2311844 | ecrin-mdr-crc

Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer

Project description:Part I of this study is designed to identify the recommended phase 2 dose (RP2D) of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant CRC. Part II is designed to obtain proof of principle of the galunisertib plus capecitabine combination in patients with chemo-resistant CRC. The combination of galunisertib plus capecitabine will be given as second line therapy in the phase II part of this study. Patients with chemotherapy resistant activated TGF-β signature-like tumors will have received a fluoropyrimidine (5FU or capecitabine) in the first line of chemotherapy, usually combined with oxaliplatin and, depending upon local hospital preferences or national guidelines, also bevacizumab, or cetuximab/panitumumab if the tumor is KRAS wild type. Addition of galunisertib to capecitabine should thus result in reversal of unresponsiveness, which is the first step in exploring this concept in the clinic. Capecitabine can be used as single agent in advanced CRC and is thus attractive for this study concept. If proof of principle is achieved also other tumor types can be explored with this genetic makeup, such as non-small cell lung cancer (NSCLC) in second line of treatment after platinum doublet therapy in first line, usually cisplatin/carboplatin-pemetrexed in non-squamous and cisplatin/carboplatin-gemcitabine or cisplatin/carboplatin-paclitaxel in squamous type NSCLC.

| 2268722 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data